SlideShare una empresa de Scribd logo
1 de 26
Tuberculosis treatment: general principles and approach Lecturer: Ph.D M.G.Dolynska
Historical background ,[object Object],[object Object],[object Object],[object Object]
The AIMS of treatment of tuberculosis are: ,[object Object],[object Object],[object Object],[object Object],[object Object]
DOTS ( Directly observed treatment short course ), Karel Styblo, 1972 ,[object Object],[object Object],[object Object],[object Object]
The five elements of the expanded DOTS framework are:   ,[object Object],[object Object],[object Object],[object Object],[object Object]
Dosage and abbreviation of essential antituberculosis drugs 30 (20-35) 15 (15-20) Ethambutol (E) 15 (12-18) 15 (12-18) Streptomycin (S) 35 (30-40) 25 (20-30) Pyrasinamide (Z) 10 (8-12) 10 (8-12) Rifampicin (R) 10 (8-12) 5 (4-6) Isoniasid (H) 3 times weekly Daily Recommended dosage (dose range) in md/kg Drug (abbreviation)
Basical treatment regimens   Optional 5 (HRE) 3 Optional 2(HRZES) 3 /1HRZE 3 Preferred 5 HRE VI Preferred 2 HRZES / 1 HRZE VI Previously treated sputum smearpositive PTB: - relapse; - treatment after default  II Optional 4 (HR)3 or 6 HE V Optional  or 2 (HRZE) 3 or 2 HRZE IV Preferred 4 HR 4 (HR)3 Preferred 2 HRZE I New smear-positive patients; new smear-negative PTB with extensive parenchymal involvement; concomitant HIV disease or severe forms of extrapulmonary TB I Continual phase Initial phase Treatment regimen I TB patients Diagnostic category
Basical treatment regimens (continued) WHO/CDS/TB/2003.313 Treatment of tuberculosis:guidelines  for national programmes, third edition. Revision approved by STAG, June 2004 Specially designed standardized or individualized regimens Chronic (still sputum-positive after supervised re-treatment); proven or suspected MDR TB cases. IV Optional 4 (HR)3 or 6 HE Optional 2 (HRZE)3 Preferred 4 HR Preferred 2 HRZE VIII New smear-negative PTB (other than in category I) and less severe forms of extra-pulmonary TB  III Continual phase Initial phase Treatment regimen I TB patients Diagnostic category
Criticism concern with the DOTS strategy ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Expanded treatment conception ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object]
Drug resistance   ,[object Object],[object Object],[object Object],[object Object]
Drug resistance ,[object Object],[object Object]
Main resistance types ,[object Object],Resistance mono MDR poly
MDR-TB  prevalence among new cases and countries in which at least one  XDR-TB  case has been reported At the end of  2006  year  XDR-TB  has been detected in 17 countries
Extensively drug resistance (XDR) – main definitions ,[object Object],[object Object]
Second line drugs ,[object Object],[object Object],[object Object]
Classes of second-line antituberculosis drugs ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Classes of second-line antituberculosis drugs ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Classes of second-line antituberculosis drugs ,[object Object],[object Object],[object Object],[object Object],[object Object]
Classes of second-line antituberculosis drugs ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Acceptable regimen for the treatment   of MDR Tuberculosis
[object Object]
Recovery criteria ,[object Object],[object Object],[object Object]
 
TB and HIV treatment sequence

Más contenido relacionado

La actualidad más candente

Chemotherapy of tuberculosis
Chemotherapy of tuberculosisChemotherapy of tuberculosis
Chemotherapy of tuberculosis
pctebpharm
 
General principles in the treatment of TB BY NAHID SHERBINI
General principles in the treatment of TB BY NAHID SHERBINIGeneral principles in the treatment of TB BY NAHID SHERBINI
General principles in the treatment of TB BY NAHID SHERBINI
Nahid Sherbini
 
Antiretroviral Drugs
Antiretroviral DrugsAntiretroviral Drugs
Antiretroviral Drugs
girlie
 
Fundamentals antimicrobial agents
Fundamentals antimicrobial agentsFundamentals antimicrobial agents
Fundamentals antimicrobial agents
raj kumar
 
chief-medical-officer--changing-roles-and-skill-sets
chief-medical-officer--changing-roles-and-skill-setschief-medical-officer--changing-roles-and-skill-sets
chief-medical-officer--changing-roles-and-skill-sets
Martha Sonnenberg
 

La actualidad más candente (20)

Antitubercular drugsnew
Antitubercular drugsnewAntitubercular drugsnew
Antitubercular drugsnew
 
Multi drug resistance (MDR TB) tuberculosis
Multi drug resistance (MDR TB) tuberculosis Multi drug resistance (MDR TB) tuberculosis
Multi drug resistance (MDR TB) tuberculosis
 
Chemotherapy of tuberculosis
Chemotherapy of tuberculosisChemotherapy of tuberculosis
Chemotherapy of tuberculosis
 
General principles in the treatment of TB BY NAHID SHERBINI
General principles in the treatment of TB BY NAHID SHERBINIGeneral principles in the treatment of TB BY NAHID SHERBINI
General principles in the treatment of TB BY NAHID SHERBINI
 
Anti tubercular drugs
Anti tubercular drugsAnti tubercular drugs
Anti tubercular drugs
 
Chloramphenicol & Clindamycin
Chloramphenicol & Clindamycin Chloramphenicol & Clindamycin
Chloramphenicol & Clindamycin
 
Pharmacotherapy of tuberculosis
Pharmacotherapy of tuberculosisPharmacotherapy of tuberculosis
Pharmacotherapy of tuberculosis
 
Beta lactams antibiotics & beta lactamase inhibitors
Beta lactams antibiotics & beta lactamase inhibitors Beta lactams antibiotics & beta lactamase inhibitors
Beta lactams antibiotics & beta lactamase inhibitors
 
Antiretroviral Drugs
Antiretroviral DrugsAntiretroviral Drugs
Antiretroviral Drugs
 
RNTCP guidelines for tuberculosis management: Extended version
RNTCP guidelines for tuberculosis management: Extended versionRNTCP guidelines for tuberculosis management: Extended version
RNTCP guidelines for tuberculosis management: Extended version
 
Fundamentals antimicrobial agents
Fundamentals antimicrobial agentsFundamentals antimicrobial agents
Fundamentals antimicrobial agents
 
chief-medical-officer--changing-roles-and-skill-sets
chief-medical-officer--changing-roles-and-skill-setschief-medical-officer--changing-roles-and-skill-sets
chief-medical-officer--changing-roles-and-skill-sets
 
Tetracyclin and chloramphenicol: Pharmacology, Mechanism of Action & Uses
Tetracyclin and chloramphenicol: Pharmacology, Mechanism of Action  & UsesTetracyclin and chloramphenicol: Pharmacology, Mechanism of Action  & Uses
Tetracyclin and chloramphenicol: Pharmacology, Mechanism of Action & Uses
 
Anti tb drugs cbme 2021 satya
Anti tb drugs cbme 2021 satya Anti tb drugs cbme 2021 satya
Anti tb drugs cbme 2021 satya
 
National Tuberculosis Elimination Programme.pptx
National Tuberculosis Elimination Programme.pptxNational Tuberculosis Elimination Programme.pptx
National Tuberculosis Elimination Programme.pptx
 
Antiretroviral
AntiretroviralAntiretroviral
Antiretroviral
 
recent guidelines in treatment of malaria,anti malarial drugs 2014
recent guidelines in treatment of malaria,anti malarial drugs 2014recent guidelines in treatment of malaria,anti malarial drugs 2014
recent guidelines in treatment of malaria,anti malarial drugs 2014
 
Anti tubercular drugs
Anti tubercular drugsAnti tubercular drugs
Anti tubercular drugs
 
Antihelminthics
AntihelminthicsAntihelminthics
Antihelminthics
 
Tuberculosis and anti tubercular drugs
Tuberculosis and anti tubercular drugsTuberculosis and anti tubercular drugs
Tuberculosis and anti tubercular drugs
 

Destacado

Treatment of Tuberculosis
Treatment of TuberculosisTreatment of Tuberculosis
Treatment of Tuberculosis
akong
 
Tuberculosis slides
Tuberculosis slidesTuberculosis slides
Tuberculosis slides
nandicinta
 
Pulmonary tuberculosis ppt
Pulmonary tuberculosis pptPulmonary tuberculosis ppt
Pulmonary tuberculosis ppt
Uma Binoy
 
Tuberculosis a brief outlook
Tuberculosis a brief outlookTuberculosis a brief outlook
Tuberculosis a brief outlook
RxVichuZ
 
Esophageal cancer-role of RT
Esophageal cancer-role of RTEsophageal cancer-role of RT
Esophageal cancer-role of RT
Bharti Devnani
 

Destacado (20)

Treatment of Tuberculosis
Treatment of TuberculosisTreatment of Tuberculosis
Treatment of Tuberculosis
 
TB treatment
TB treatmentTB treatment
TB treatment
 
Tuberculosis slides
Tuberculosis slidesTuberculosis slides
Tuberculosis slides
 
Pharmacotherapy of TUBERCULOSIS
Pharmacotherapy of TUBERCULOSISPharmacotherapy of TUBERCULOSIS
Pharmacotherapy of TUBERCULOSIS
 
Anti tuberculosis drugs
Anti tuberculosis drugsAnti tuberculosis drugs
Anti tuberculosis drugs
 
Pulmonary tuberculosis..ptt
Pulmonary tuberculosis..pttPulmonary tuberculosis..ptt
Pulmonary tuberculosis..ptt
 
Pulmonary tuberculosis ppt
Pulmonary tuberculosis pptPulmonary tuberculosis ppt
Pulmonary tuberculosis ppt
 
WHO and RNTCP guidelines - Tuberculosis management
WHO and RNTCP guidelines - Tuberculosis managementWHO and RNTCP guidelines - Tuberculosis management
WHO and RNTCP guidelines - Tuberculosis management
 
Tuberculosis presentation
Tuberculosis presentationTuberculosis presentation
Tuberculosis presentation
 
Tuberculosis a brief outlook
Tuberculosis a brief outlookTuberculosis a brief outlook
Tuberculosis a brief outlook
 
Mdr tb khaled latest
Mdr tb khaled latestMdr tb khaled latest
Mdr tb khaled latest
 
Esophageal cancer-role of RT
Esophageal cancer-role of RTEsophageal cancer-role of RT
Esophageal cancer-role of RT
 
Diagnosis of tuberculosis
Diagnosis of tuberculosisDiagnosis of tuberculosis
Diagnosis of tuberculosis
 
Principle of mdr tb management
Principle of mdr tb managementPrinciple of mdr tb management
Principle of mdr tb management
 
Tuberculosis
TuberculosisTuberculosis
Tuberculosis
 
published paper
published paperpublished paper
published paper
 
C0342010014
C0342010014C0342010014
C0342010014
 
Diagnosis of Pulmonary Tuberculosis
Diagnosis of Pulmonary TuberculosisDiagnosis of Pulmonary Tuberculosis
Diagnosis of Pulmonary Tuberculosis
 
Bioavailability of drug through iv,im
Bioavailability of drug through iv,imBioavailability of drug through iv,im
Bioavailability of drug through iv,im
 
Plaster of Paris
Plaster of ParisPlaster of Paris
Plaster of Paris
 

Similar a Tuberculosis treatment

Mdr xdr TB
Mdr xdr TBMdr xdr TB

Similar a Tuberculosis treatment (20)

Mdr tb & xdr tb ppt.
Mdr tb & xdr tb ppt. Mdr tb & xdr tb ppt.
Mdr tb & xdr tb ppt.
 
Mdr, xdr by dr tasleem arif
Mdr, xdr by dr tasleem arifMdr, xdr by dr tasleem arif
Mdr, xdr by dr tasleem arif
 
MDR/XDR by Dr Tasleem Arif
MDR/XDR by Dr Tasleem ArifMDR/XDR by Dr Tasleem Arif
MDR/XDR by Dr Tasleem Arif
 
WHO GUIDE LINE ON MDR.pptx
WHO GUIDE LINE ON MDR.pptxWHO GUIDE LINE ON MDR.pptx
WHO GUIDE LINE ON MDR.pptx
 
DRUG RESISTANT TUBERCULOSIS,DIAGNOSIS AND TREATMENT
DRUG RESISTANT TUBERCULOSIS,DIAGNOSIS AND TREATMENTDRUG RESISTANT TUBERCULOSIS,DIAGNOSIS AND TREATMENT
DRUG RESISTANT TUBERCULOSIS,DIAGNOSIS AND TREATMENT
 
Drugresistanttuberculosis 100227020029 Phpapp01
Drugresistanttuberculosis 100227020029 Phpapp01Drugresistanttuberculosis 100227020029 Phpapp01
Drugresistanttuberculosis 100227020029 Phpapp01
 
Management of mdr tb and role of pharmacist
Management of mdr tb and role of pharmacistManagement of mdr tb and role of pharmacist
Management of mdr tb and role of pharmacist
 
Introduction to drugs for tuberculosis and leprosy
Introduction to drugs for tuberculosis and leprosyIntroduction to drugs for tuberculosis and leprosy
Introduction to drugs for tuberculosis and leprosy
 
1INTRO~1.PPT
1INTRO~1.PPT1INTRO~1.PPT
1INTRO~1.PPT
 
Management of DR-TB
Management of DR-TBManagement of DR-TB
Management of DR-TB
 
Mdr tuberculosis
Mdr tuberculosisMdr tuberculosis
Mdr tuberculosis
 
Treatment of childhood tb
Treatment of childhood tbTreatment of childhood tb
Treatment of childhood tb
 
Updated Part -3 Management of TB.. DR. Kiran G. Piparva 2020 [Autosaved].pptx
Updated Part -3 Management of TB.. DR. Kiran G. Piparva 2020 [Autosaved].pptxUpdated Part -3 Management of TB.. DR. Kiran G. Piparva 2020 [Autosaved].pptx
Updated Part -3 Management of TB.. DR. Kiran G. Piparva 2020 [Autosaved].pptx
 
A case of MDR-TB
A case of MDR-TBA case of MDR-TB
A case of MDR-TB
 
Drug therapy for TB
Drug therapy for TBDrug therapy for TB
Drug therapy for TB
 
New Drugs and Novel Approaches to Treatment Shortening for Drug-Susceptible a...
New Drugs and Novel Approaches to Treatment Shortening for Drug-Susceptible a...New Drugs and Novel Approaches to Treatment Shortening for Drug-Susceptible a...
New Drugs and Novel Approaches to Treatment Shortening for Drug-Susceptible a...
 
Tb seminar by rs
Tb seminar by rsTb seminar by rs
Tb seminar by rs
 
Multi Drug Resistant Tuberculosis
Multi Drug Resistant Tuberculosis Multi Drug Resistant Tuberculosis
Multi Drug Resistant Tuberculosis
 
Multi drug resistant tuberculosis
Multi drug resistant tuberculosisMulti drug resistant tuberculosis
Multi drug resistant tuberculosis
 
Mdr xdr TB
Mdr xdr TBMdr xdr TB
Mdr xdr TB
 

Último

The basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxThe basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptx
heathfieldcps1
 

Último (20)

On National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan FellowsOn National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan Fellows
 
Jamworks pilot and AI at Jisc (20/03/2024)
Jamworks pilot and AI at Jisc (20/03/2024)Jamworks pilot and AI at Jisc (20/03/2024)
Jamworks pilot and AI at Jisc (20/03/2024)
 
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
 
Single or Multiple melodic lines structure
Single or Multiple melodic lines structureSingle or Multiple melodic lines structure
Single or Multiple melodic lines structure
 
Key note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfKey note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdf
 
Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024
 
Food safety_Challenges food safety laboratories_.pdf
Food safety_Challenges food safety laboratories_.pdfFood safety_Challenges food safety laboratories_.pdf
Food safety_Challenges food safety laboratories_.pdf
 
Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...
Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...
Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...
 
Towards a code of practice for AI in AT.pptx
Towards a code of practice for AI in AT.pptxTowards a code of practice for AI in AT.pptx
Towards a code of practice for AI in AT.pptx
 
Sociology 101 Demonstration of Learning Exhibit
Sociology 101 Demonstration of Learning ExhibitSociology 101 Demonstration of Learning Exhibit
Sociology 101 Demonstration of Learning Exhibit
 
SOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning PresentationSOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning Presentation
 
General Principles of Intellectual Property: Concepts of Intellectual Proper...
General Principles of Intellectual Property: Concepts of Intellectual  Proper...General Principles of Intellectual Property: Concepts of Intellectual  Proper...
General Principles of Intellectual Property: Concepts of Intellectual Proper...
 
Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdf
 
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptxBasic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
 
How to Add New Custom Addons Path in Odoo 17
How to Add New Custom Addons Path in Odoo 17How to Add New Custom Addons Path in Odoo 17
How to Add New Custom Addons Path in Odoo 17
 
Plant propagation: Sexual and Asexual propapagation.pptx
Plant propagation: Sexual and Asexual propapagation.pptxPlant propagation: Sexual and Asexual propapagation.pptx
Plant propagation: Sexual and Asexual propapagation.pptx
 
NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...
NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...
NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...
 
80 ĐỀ THI THỬ TUYỂN SINH TIẾNG ANH VÀO 10 SỞ GD – ĐT THÀNH PHỐ HỒ CHÍ MINH NĂ...
80 ĐỀ THI THỬ TUYỂN SINH TIẾNG ANH VÀO 10 SỞ GD – ĐT THÀNH PHỐ HỒ CHÍ MINH NĂ...80 ĐỀ THI THỬ TUYỂN SINH TIẾNG ANH VÀO 10 SỞ GD – ĐT THÀNH PHỐ HỒ CHÍ MINH NĂ...
80 ĐỀ THI THỬ TUYỂN SINH TIẾNG ANH VÀO 10 SỞ GD – ĐT THÀNH PHỐ HỒ CHÍ MINH NĂ...
 
The basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxThe basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptx
 
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdf
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdfUnit 3 Emotional Intelligence and Spiritual Intelligence.pdf
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdf
 

Tuberculosis treatment

  • 1. Tuberculosis treatment: general principles and approach Lecturer: Ph.D M.G.Dolynska
  • 2.
  • 3.
  • 4.
  • 5.
  • 6. Dosage and abbreviation of essential antituberculosis drugs 30 (20-35) 15 (15-20) Ethambutol (E) 15 (12-18) 15 (12-18) Streptomycin (S) 35 (30-40) 25 (20-30) Pyrasinamide (Z) 10 (8-12) 10 (8-12) Rifampicin (R) 10 (8-12) 5 (4-6) Isoniasid (H) 3 times weekly Daily Recommended dosage (dose range) in md/kg Drug (abbreviation)
  • 7. Basical treatment regimens Optional 5 (HRE) 3 Optional 2(HRZES) 3 /1HRZE 3 Preferred 5 HRE VI Preferred 2 HRZES / 1 HRZE VI Previously treated sputum smearpositive PTB: - relapse; - treatment after default II Optional 4 (HR)3 or 6 HE V Optional or 2 (HRZE) 3 or 2 HRZE IV Preferred 4 HR 4 (HR)3 Preferred 2 HRZE I New smear-positive patients; new smear-negative PTB with extensive parenchymal involvement; concomitant HIV disease or severe forms of extrapulmonary TB I Continual phase Initial phase Treatment regimen I TB patients Diagnostic category
  • 8. Basical treatment regimens (continued) WHO/CDS/TB/2003.313 Treatment of tuberculosis:guidelines for national programmes, third edition. Revision approved by STAG, June 2004 Specially designed standardized or individualized regimens Chronic (still sputum-positive after supervised re-treatment); proven or suspected MDR TB cases. IV Optional 4 (HR)3 or 6 HE Optional 2 (HRZE)3 Preferred 4 HR Preferred 2 HRZE VIII New smear-negative PTB (other than in category I) and less severe forms of extra-pulmonary TB III Continual phase Initial phase Treatment regimen I TB patients Diagnostic category
  • 9.
  • 10.
  • 11.
  • 12.
  • 13.
  • 14.
  • 15. MDR-TB prevalence among new cases and countries in which at least one XDR-TB case has been reported At the end of 2006 year XDR-TB has been detected in 17 countries
  • 16.
  • 17.
  • 18.
  • 19.
  • 20.
  • 21.
  • 22. Acceptable regimen for the treatment of MDR Tuberculosis
  • 23.
  • 24.
  • 25.  
  • 26. TB and HIV treatment sequence